ImmunityBio says ANKTIVA plus BCG meets primary endpoint in Phase 3 NMIBC trial, supports planned FDA filing

ImmunityBio says ANKTIVA plus BCG met the primary endpoint in its Phase 3 NMIBC trial, supporting a planned FDA filing.

Detected & updated continuously · Source: Nebula